Long-term antipsychotic polypharmacy in the VA Health System: Patient characteristics and treatment patterns

Psychiatric Services

Volumn 58, Issue 4, 2007, Pages 489-495

  Kreyenbuhl, Julie A ^a,b   Valenstein, Marcia ^c   McCarthy, John F ^c   Ganoczy, Dara ^c   Blow, Frederic C ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c VA Serious Mental Illness Treatment Research and Evaluation Center   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 34247371922     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.4.489     Document Type: Article

References (31)

1. Canales PL, Olsen J, Miller AL, et al: Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 12:179-188, 1999
2. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
3. Centorrino F, Fogarty KV, Sani G, et al: Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Human Psychopharmacology: Clinical and Experimental 20:485-492, 2005
4. Centorrino F, Goren JL, Hennen J, et al: Multiple versus single antipsychotic agents for hospitalized patients: case control study of risks versus benefits. American Journal of Psychiatry 161:700-706, 2004
5. Ganguly R, Kotzan JA, Miller S, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65:1377-1388, 2004
6. Humberstone V, Wheeler A, Lambert T: An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry 38:240-245, 2004
7. Procyshyn RM, Thompson B: Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 37:12-17, 2004
8. Jaffe AB, Levine J: Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and Drug Safety 12:41-48, 2003
9. Tapp A, Wood AE, Secrest L, et al: Combination antipsychotic therapy in clinical practice. Psychiatric Services 54:55-59, 2003
10. Tempier RP, Pawliuk NH: Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. Journal of Clinical Psychiatry 64:673-679, 2003
11. Covell NH, Jackson CT, Evans AC, et al: Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28:17-29, 2002
12. Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York Metropolitan Region. Schizophrenia Bulletin 28:31-42, 2002
13. Leslie DL, Rosenheck RA: Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Medical Care 39:923-933, 2001
14. Procyshyn RM, Kennedy NB, Tse G, et al: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Canadian Journal of Psychiatry 46:334-339, 2001
15. Honer WG, Thornton AE, Chen EYH, et al: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine 354: 472-482, 2006
16. Josiassen RC, Joseph A, Kohegyi E, et al: Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 162:130-136, 2005
17. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al: A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry 66:63-72, 2005
18. Shiloh R, Zemishlany A, Aizenberg D, et al: Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. British Journal of Psychiatry 171:569-573, 1997
19. Potter WZ, Ko GN, Zhang LD, et al: Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berlin) 99(suppl):S87-S91, 1989
20. Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica 106:323-330, 2002
21. Stahl SM, Grady MM: A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry 11:313-327, 2004
22. Joukamaa M, Heliovaara M, Knekt P, et al: Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 188:122-127, 2006
23. Waddington JL, Youssef JA, Kinsella A: Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173:325-329, 1998
24. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65:500-508, 2004
25. Kreyenbuhl J, Valenstein M, McCarthy JF, et al: Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 84:90-99, 2006
26. Blow FC, McCarthy JF, Valenstein M, et al: Care in the VHA for Veterans With Psychosis 1999. Ann Arbor, Mich, Veterans Health Administration Health Services Research and Development, 2000
27. Blow FC, McCarthy JF, Valenstein M, et al: Care in the VHA for Veterans With Psychoses FY00: 2nd Annual National Psychoses Registry Report. Ann Arbor, Mich, Veterans Health Administration Health Services Research and Development, 2001
28. Blow FC, McCarthy JF, Valenstein M, et al: Care in the VHA for Veterans With Psychoses FY01: 3rd Annual National Psychoses Registry Report. Ann Arbor, Mich, Veterans Health Administration Health Services Research and Development, 2001
29. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease 40:373-383, 1987
30. Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30:193-217, 2004
31. Sernyak MJ, Rosenheck R: Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 65:1597-1600, 2004